Neuland Laboratories Ltd

Neuland Labs. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Neuland Laboratories Ltd

₹ 11,186 -0.10%
23 May 12:30 p.m.
neulandlabs.com BSE: 524558 NSE: NEULANDLAB
About

Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets.[1]

Key Points

Business Segments
1. Prime APIs
This segment comprises ~15 mature large volume APIs in a highly competitive market. The key molecules in this primary revenue generating segment are Levetiracetam and Mirtazapine. [1]

Website BSE NSE
  • Market Cap ₹ 14,352 Cr.
  • Current Price ₹ 11,186
  • High / Low ₹ 18,100 / 5,540
  • Stock P/E 71.0
  • Book Value ₹ 1,183
  • Dividend Yield 0.13 %
  • ROCE 18.2 %
  • ROE 14.5 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has delivered good profit growth of 66.6% CAGR over last 5 years

Cons

  • Stock is trading at 9.54 times its book value
  • Earnings include an other income of Rs.96.9 Cr.
  • Promoter holding has decreased over last 3 years: -3.54%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs

Part of BSE Healthcare Nifty 500 BSE SmallCap Nifty Smallcap 100 BSE Allcap

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
256 221 294 269 407 363 418 393 385 440 311 398 328
217 193 225 215 287 266 280 272 278 316 250 312 278
Operating Profit 39 28 69 54 120 97 137 121 107 124 61 86 51
OPM % 15% 13% 24% 20% 29% 27% 33% 31% 28% 28% 20% 22% 15%
1 1 0 1 8 2 3 2 5 25 4 60 7
Interest 3 3 3 3 4 2 4 4 4 3 1 2 2
Depreciation 12 13 13 13 13 14 15 15 16 16 16 16 17
Profit before tax 24 13 53 39 110 84 121 104 92 130 49 128 39
Tax % 9% 26% 28% 22% 23% 25% 27% 22% 27% 25% 34% 20% 29%
22 10 38 30 85 62 89 81 68 98 32 101 28
EPS in Rs 17.01 7.67 29.88 23.73 65.87 48.50 69.42 62.90 52.70 76.65 24.91 79.03 21.61
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
466 469 510 579 527 667 763 937 951 1,191 1,559 1,477
395 402 430 473 477 609 661 790 807 919 1,096 1,155
Operating Profit 70 67 80 106 50 58 101 147 144 272 462 322
OPM % 15% 14% 16% 18% 10% 9% 13% 16% 15% 23% 30% 22%
3 0 2 1 4 3 4 16 0 9 12 97
Interest 25 27 24 21 19 16 22 18 13 13 14 8
Depreciation 15 15 16 19 22 26 31 40 49 53 60 66
Profit before tax 34 24 41 67 14 20 52 105 82 215 401 345
Tax % 22% 36% 36% 30% 13% 19% 70% 23% 22% 24% 25% 25%
27 16 26 46 12 16 16 80 64 163 300 259
EPS in Rs 29.97 17.76 29.73 52.20 13.29 12.58 12.38 62.58 49.52 127.14 233.52 202.21
Dividend Payout % 9% 9% 7% 0% 0% 0% 16% 8% 10% 8% 6% 6%
Compounded Sales Growth
10 Years: 12%
5 Years: 14%
3 Years: 16%
TTM: -5%
Compounded Profit Growth
10 Years: 29%
5 Years: 67%
3 Years: 46%
TTM: -33%
Stock Price CAGR
10 Years: 41%
5 Years: 91%
3 Years: 122%
1 Year: 80%
Return on Equity
10 Years: 12%
5 Years: 16%
3 Years: 19%
Last Year: 14%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 8 9 9 9 9 13 13 13 13 13 13 13
Reserves 115 151 175 534 546 683 693 769 823 975 1,264 1,505
190 188 182 192 319 231 264 182 241 128 95 157
171 164 157 150 197 203 260 359 306 463 459 503
Total Liabilities 483 511 523 885 1,071 1,130 1,230 1,324 1,382 1,579 1,831 2,178
131 123 139 466 475 541 653 716 767 758 824 958
CWIP 35 41 40 20 126 104 24 17 20 41 46 45
Investments 8 8 8 8 8 8 8 7 4 1 1 109
310 339 337 392 462 476 545 583 590 781 960 1,066
Total Assets 483 511 523 885 1,071 1,130 1,230 1,324 1,382 1,579 1,831 2,178

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
49 13 45 39 12 70 57 189 60 239 260 317
-10 -14 -20 -42 -116 -77 -49 -84 -96 -62 -150 -298
-39 1 -24 -0 105 12 -5 -114 38 -136 -69 25
Net Cash Flow 0 0 1 -3 0 4 2 -9 3 41 41 44

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 93 100 85 114 134 90 91 85 90 111 87 78
Inventory Days 138 170 182 188 268 191 209 205 227 211 220 240
Days Payable 138 167 124 123 198 123 114 130 105 135 125 162
Cash Conversion Cycle 93 103 144 179 205 158 186 160 212 187 183 156
Working Capital Days 87 123 113 137 174 124 128 92 122 94 96 113
ROCE % 19% 16% 18% 16% 4% 4% 8% 11% 10% 21% 33% 18%

Shareholding Pattern

Numbers in percentages

6 Recently
Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
36.22% 36.22% 36.14% 36.14% 36.03% 35.97% 32.80% 32.74% 32.72% 32.64% 32.68% 32.67%
17.39% 17.68% 17.70% 18.14% 20.19% 21.57% 22.69% 24.43% 25.72% 26.46% 23.86% 22.12%
6.45% 6.57% 6.54% 7.10% 6.76% 6.99% 6.02% 6.54% 6.39% 6.38% 9.09% 10.97%
0.00% 0.44% 0.46% 0.40% 0.40% 0.40% 0.40% 0.40% 0.40% 0.40% 0.40% 0.40%
39.94% 39.07% 39.15% 38.22% 36.62% 35.08% 38.10% 35.88% 34.77% 34.12% 33.96% 33.85%
No. of Shareholders 31,97630,60029,66926,94825,22326,82427,72328,61629,07734,56739,31539,333

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Right Issue

Credit ratings

Concalls